What Happened to Danuglipron? Pfizer’s Oral Weight Loss Pill Explained

Danuglipron was Pfizer’s attempt at an oral GLP-1 weight-loss pill, and the short answer to what happened is that Pfizer discontinued it in April 2025 after a single case of possible liver injury in a study participant. It followed an earlier setback in 2023, when the twice-daily version was dropped over tolerability problems. The drug actually worked, producing real weight loss, but safety and competitive pressures ended the program. Here’s the full story and why it matters for the broader race to make a weight-loss pill.

The Appeal of a Pill

Most effective weight-loss drugs are injections, so a convenient daily pill that delivers similar results has been a major goal across the industry. Danuglipron was Pfizer’s leading candidate: an oral small-molecule drug that activates the GLP-1 receptor, the same target as semaglutide, but in pill form. If it had succeeded, it would have given Pfizer a way to compete with Eli Lilly and Novo Nordisk in a market analysts value in the tens of billions.

The drug did show it could work. A trial of danuglipron in type 2 diabetes, published in JAMA Network Open in 2023, demonstrated that the oral drug improved blood sugar control, and separate obesity studies showed meaningful weight loss. The problem was never whether it reduced weight. It was everything around that.

The Two Setbacks

Danuglipron’s downfall came in two stages.

In the final chapter, Pfizer said the once-daily formulation had actually met its key technical goals and looked competitive. But after one asymptomatic case of potential liver injury (which resolved when the drug was stopped), combined with the overall profile and regulatory feedback, the company decided to discontinue development.

Why One Case Ended It

It might seem surprising that a single liver-injury case would end an entire program, but context matters. Liver enzyme elevations have been a recurring concern for oral weight-loss drugs, and Pfizer had already dropped an earlier oral GLP-1 (lotiglipron) in 2023 over liver signals. With intense competition, high safety expectations for drugs meant to be taken by millions of otherwise healthy people, and regulator input, Pfizer judged the risk-benefit balance unfavorable. Consider a hypothetical future patient taking a weight-loss pill daily for years: the safety bar for that kind of long-term, widespread use is understandably high.

What This Means for You Right Now

Danuglipron will not be coming to market, so it isn’t something to wait for, and TrimRx never offered it. TrimRx provides medications that are available today, including compounded semaglutide and compounded tirzepatide plus brand options like Ozempic, Wegovy, Mounjaro, and Zepbound. The oral weight-loss pill race continues with other candidates, but danuglipron is out of it.

The takeaway from the danuglipron story isn’t that oral GLP-1 pills are doomed. It’s that the safety standards for them are demanding, and not every promising candidate makes it.

Frequently Asked Questions

Why was danuglipron discontinued?

Pfizer discontinued danuglipron in April 2025 after a single study participant experienced possible drug-induced liver injury. This followed an earlier 2023 decision to drop the twice-daily version because of poor tolerability (nausea and vomiting). The drug produced weight loss, but safety and competitive factors ended it.

Did danuglipron actually work for weight loss?

Yes. Danuglipron produced meaningful weight loss in obesity studies and improved blood sugar in diabetes trials. Its problems were tolerability and a liver-safety signal, not a lack of efficacy.

Is there still an oral weight-loss pill coming?

Yes, other oral candidates are in development from various companies, and one oral GLP-1 has already been approved. Danuglipron simply isn’t among the survivors. TrimRx offers currently available injectable and compounded options rather than investigational pills.

To focus on treatments you can actually use now, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Danuglipron’s development has been discontinued and it is not available. Consult a healthcare provider before starting any medication. Individual results may vary.